Medicenna Therapeutics (MDNA) PT Lowered to $7 at Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MDNA Hot Sheet
Price: $0.16 --0%
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
1 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Maxim Group analyst Naureen Quibria lowered the price target on Medicenna Therapeutics (NASDAQ: MDNA) to $7.00 (from $9.00) while maintaining a Buy rating.
You May Also Be Interested In
- Fortune Brands (FBIN) PT Lowered to $58 at DA Davidson
- Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders
- DuPont (DD) PT Raised to $182 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
